Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...

Recent commentary has highlighted CRISPR Therapeutics’ expanding gene-editing pipeline, including cardiovascular candidates like CTX310 and CTX320 and programs in type 1 diabetes, alongside fresh Buy ...

A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.

At the heart of this technology is the Cas9 protein, often likened to molecular scissors, capable of cutting strands of DNA at specific locations dictated by a single guide RNA. With this mechanism, ...

The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the ...

Wondering if CRISPR Therapeutics at around US$51.22 is pricing in too much hope or leaving room on the table? This article walks through what the current share price may be implying about the company.

A new generation of CRISPR technology developed at UNSW Sydney offers a safer path to treating genetic diseases like Sickle Cell, while also proving beyond doubt that chemical tags on DNA — often ...

NANJING, China, Dec. 7, 2023 /PRNewswire/ -- The rapid advancement of technology has propelled the field of life sciences into unprecedented growth, constantly expanding our understanding and ...

Crispr Therapeutics AG's current revenue from CASGEVY is limited by high costs, profit-sharing, and logistical hurdles, making future pipeline progress critical. Management is focused on improving ...

In the first of a new series of GEN Keynote Webinars, Professor Rodolphe Barrangou, PhD (North Carolina State; EIC, The CRISPR Journal) offers a front-row perspective of the CRISPR revolution, the ...